相关实验视频

Updated: Jan 17, 2026

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Synthesis, Functionalization, and Characterization of Fusogenic Porous Silicon Nanoparticles for Oligonucleotide Delivery

Published on: April 16, 2019

针对肝细胞中的胰岛素抵抗:一种通过先进的纳米载体系统传递的新型胰岛素模拟剂

Mihaela Turtoi¹, Mariana Deleanu², Maria Anghelache¹

¹Medical and Pharmaceutical Bionanotechnologies" Laboratory, Institute of Cellular Biology and Pathology "Nicolae Simionescu" of the Romanian Academy, 8 B.P. Hasdeu street, Bucharest 050568, Romania.

ACS pharmacology & translational science

|September 19, 2025

概括

一种新型的复合物 (Van) 在2型糖尿病 (T2DM) 模型中有效逆转肝脏胰岛素抵抗 (IR). 纳米技术增强了范的能力.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
纳米技术纳米技术

背景情况:

肝脏胰岛素抵抗 (IR) 是2型糖尿病 (T2DM) 发病的一个关键因素.
化合物显示出抗糖尿病潜力,但面临毒性限制.
新型希夫基核双核氧化--V复合体 (Van) 开发用于IR处理.

研究的目的:

使用体外IR-HepG2细胞模型研究Van在逆转肝脏IR中的有效性.
阐明Van在恢复胰岛素敏感性的药理机制.
评估Van的脂质体封装作为一种纳米治疗策略,以增强细胞吸收和有效性.

主要方法:

使用了体外肝癌 (HepG2) 细胞模型,该细胞经受胰岛素抵抗 (IR-HepG2) 的影响.
评估了Van对葡萄糖吸收,糖原合成和脂质积累的影响.
研究了涉及PTP-1B,InsR/AKT/GSK-3αβ通路,G6Pase,PCK1和GLUT-2的分子机制.
将Van封装成脂质体,以创建一个纳米治疗输送系统.

主要成果:

范通过改善葡萄糖吸收,糖原合成和减少脂质积累,有效地逆转了IR在IR-HepG2细胞中的IR.
范抑制了PTP-1B的表达和活性,激活了InsR/AKT/GSK-3αβ通路.
与自由的Van相比,脂质组Van显著增强了细胞吸收和治疗疗效.
范成功地降低了G6Pase表达,同时保持了PCK1和GLUT-2水平.

结论:

这种新型的Van复合体在逆转肝脏IR方面显示出显著的潜力,这是T2DM的关键驱动因素.
范的机制涉及调节关键信号通路和葡萄糖代谢酶.
体输送Van增强了其治疗效果,为T2DM提供了一个有前途的纳米治疗方法.

关键词:

肝癌细胞系细胞系的肝癌.胰岛素耐药性是一种胰岛素耐药性.脂质体是一种脂质体.氧化瓦纳 (V) 复合体 2 型糖尿病 2 型糖尿病

更多相关视频

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer

Published on: October 10, 2012

相关概念视频

Insulin: The Receptor and Signaling Pathways

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Insulin: Biosynthesis, Chemistry, and Preparation

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...